This structural information of HLAL along with MD simulation speculations may help to develop pharmacological agents that either rescue trafficking or folding defects or increase the functional activity of LAL, providing a path to an effective therapeutic option for WD and CESD patients. The gene discussed is HLA-L; the disease is cholesteryl ester storage disease.